Aquilo

Aquilo Capital Management is a biotech-focused investment firm based in San Francisco, established in 2010. The firm specializes in funding drug development companies that utilize cutting-edge science to address urgent medical needs. Aquilo’s approach is rooted in deep sector expertise and a disciplined, value-oriented investment strategy. They focus on identifying biotech companies with the potential to create transformative therapeutics that can significantly impact healthcare and society. The firm’s investment strategy is heavily concentrated in life sciences, targeting innovative drug discovery and development projects. They aim to balance risk with high potential returns, favoring companies that are on the cusp of delivering paradigm-shifting treatments. Aquilo employs both a long-only and hedged investment strategy, giving them flexibility and resilience in volatile markets. Notable investments include pioneering biotech firms like Arrowhead Pharmaceuticals and Regenxbio. Aquilo Capital is led by founder and CIO Marc Schneidman, who brings over 20 years of experience in the biotech investment space. The firm takes a global perspective, with a keen interest in leveraging opportunities in both the U.S. and Europe. They are known for supporting early-stage ventures and maintaining strong relationships with the scientific and biotech communities. Aquilo’s mission is to bridge the gap between groundbreaking science and successful commercial application, delivering both societal benefits and strong returns for investors.